Search

Your search keyword '"Byetta (Medication)"' showing total 827 results
Start Over Descriptor "Byetta (Medication)"
827 results on '"Byetta (Medication)"'

1. What We've Learned About GLP-1 Agonists to Date: Some of these drugs reduce the risk of heart attack and stroke in people with diabetes and in obese individuals without diabetes

Subjects
United States. Food and Drug Administration, Heart attack -- Drug therapy -- Risk factors, Diabetes therapy, Drugs, Hypoglycemic agents, Blood sugar, Drug approval, Type 2 diabetes -- Drug therapy -- Risk factors, Diabetics -- Drug therapy, Weight loss -- Risk factors -- Drug therapy, Health, Ozempic (Medication), Wegovy (Medication), Byetta (Medication), Zepbound (Medication)
Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to lower blood glucose (sugar) levels in individuals with type 2 diabetes. The first GLP-1, exenatide (Byetta), was approved [...]

Published
2024

2. Tracon Pharmaceuticals appoints Dongliang Zhang as VP, statistics and biometrics

Subjects
United States. Food and Drug Administration -- Officials and employees, Executives, Business, News, opinion and commentary, Byetta (Medication)
Abstract

TRACON Pharmaceuticals announced the appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics.. Following his time at the U.S. FDA, he served as the Head of Biostatistics [...]

Published
2021

3. ADA 2021: AstraZeneca touts Bydureon trial win in children and adolescents with type 2 diabetes

Author

Dunleavy, Kevin

Subjects
Merck & Company Inc., AstraZeneca PLC, Novo Nordisk A/S, Eli Lilly and Co., Type 2 diabetes, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, Byetta (Medication), Bydureon (Medication)
Abstract

Byline: Kevin Dunleavy As it approaches the end of a distinguished run, AstraZeneca's type 2 diabetes franchise is showing its age. Sales are in decline for Byetta and Bydureon as [...]

Published
2021

4. TRACON Pharmaceuticals appoints Dongliang Zhuang as Vice President of Statistics and Biometrics

Subjects
United States. Food and Drug Administration -- Officials and employees, Executives, General interest, News, opinion and commentary, Byetta (Medication)
Abstract

SAN DIEGO: TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, announced the appointment of Dongliang Zhuang, Ph.D. as Vice President [...]

Published
2021

5. On a tear: medical/surgical journal advertising grew in 2011, the second consecutive year it's been in the black. Marc Iskowitz on which categories and brands attracted the most advertising dollars

Author

Iskowitz, Marc

Subjects
Merck & Company Inc., Takeda Pharmaceutical Company Ltd., Johnson & Johnson, Pfizer Inc., Roche A/S, Novartis AG, Forest Pharmaceuticals Inc., Eli Lilly and Co., Abbott Laboratories (Abbott Park, Illinois), Sanofi S.A., Advertising, Magazine advertising, Professional workers, Brand name products, Pharmaceutical industry, Business, Health care industry, Alimta (Medication), Evista (Medication), Xgeva (Medication), Viibryd (Medication), Savella (Medication), Victoza (Medication), Viagra (Medication), Daliresp (Medication), Evoxac (Medication), Teflaro (Medication), Bystolic (Medication), Butrans (Transdermal patch), Prolia (Medication), Brilinta (Medication), Cymbalta (Medication), Dexilant (Medication), Forteo (Medication), Pradaxa (Medication), Humalog (Medication), Lantus (Medication), Effient (Medication), Byetta (Medication), Lyrica (Medication), Xarelto (Medication)
Abstract

Call 2011 the year of restrained recovery. Sounds paradoxical? Perhaps, but we've learned to look at professional journal advertising as the glass that's both half-empty and half-full. The optimist sees [...]

Published
2012

6. Down but not out: the last thing medical/surgical journals needed was a recession. James Chase teams up with Kantar Media to chart the biggest advertisers and the most advertised categories and brands of '09

Author

Chase, James

Subjects
Merck & Company Inc. -- Alliances and partnerships, Amgen Inc. -- Alliances and partnerships, Genentech Inc. -- Alliances and partnerships, Pfizer Inc. -- Alliances and partnerships, Janssen Pharmaceutica Inc. -- Alliances and partnerships, AstraZeneca PLC -- Alliances and partnerships, Teva Pharmaceutical Industries Ltd. -- Alliances and partnerships, Novo Nordisk A/S -- Alliances and partnerships, Schering-Plough Corp. -- Alliances and partnerships, Eli Lilly and Co. -- Alliances and partnerships, Abbott Laboratories (Abbott Park, Illinois) -- Alliances and partnerships, Sanofi-Aventis S.A. -- Alliances and partnerships, Wyeth -- Alliances and partnerships, Gilead Sciences Inc. -- Alliances and partnerships, Novartis AG -- Alliances and partnerships, GlaxoSmithKline PLC -- Alliances and partnerships, Forest Laboratories Inc. -- Alliances and partnerships, Laboratoires Takeda -- Alliances and partnerships, Advertising expenditures, Alzheimer's disease -- Drug therapy, Antilipemic agents, Medical journals, Magazine advertising, Pharmaceutical industry -- Alliances and partnerships, Business, Health care industry, Toviaz (Medication), Pristiq (Medication), Savella (Medication), Levenir (Medication), Namenda (Medication), Bystolic (Medication), Lipitor (Medication), Cymbalta (Medication), Januvia (Medication), Humalog (Medication), Kapidex (Medication), Uloric (Medication), Byetta (Medication), Lexapro (Medication), Avastin (Medication)
Abstract

It is, perhaps, difficult to imagine right now, but as recently as 2006 medical surgical journal revenues were still on the up. Not much of an up, perhaps--in 2006, ad [...]

Published
2010

7. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

8. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

9. Diabetes drugs: an update on what's new; So many new antihyperglycemic agents have debuted that doctors can't keep up. An endocrinologist/diabetologist provides a refresher

Author

Mitzner, Lyle

Subjects
Diabetes therapy, Diabetes -- Drug therapy, Hypoglycemic agents, Health, Symlin (Medication), Exubera (Medication), Byetta (Medication)
Abstract

We all know a diabetes epidemic is upon us, afflicting 21 million Americans and claiming more patients each day. But there's good news too. Several new diabetes therapies have been [...]

Published
2007

10. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

11. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

12. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

13. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

14. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2018

15. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

16. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

17. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

18. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

19. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

20. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Nexium (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

21. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

22. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

23. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

24. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

25. AstraZeneca (NYSE: AZN)

Subjects
Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

26. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

27. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

28. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

29. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

30. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

31. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

32. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

33. AstraZeneca (NYSE: AZN)

Subjects
Benralizumab, Autoimmunity, Infection, Neurosciences, Production management, Business, international, Brilinta (Medication), Bydureon (Medication), Byetta (Medication), Crestor (Medication), Farxiga (Medication), Faslodex (Medication), Lynparza (Medication), Nexium 24HR (Medication), Onglyza (Medication), Seroquel (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

34. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

35. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

36. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

37. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

38. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

39. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

40. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

41. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

42. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

43. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

44. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

45. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

46. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

47. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

48. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Crestor (Medication), Lynparza (Medication), Bydureon (Medication), Tagrisso (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

49. AstraZeneca (NYSE: AZN)

Subjects
Autoimmunity, Business, international, Seroquel (Medication), Brilinta (Medication), Farxiga (Medication), Faslodex (Medication), Onglyza (Medication), Nexium 24HR (Medication), Byetta (Medication), Lynparza (Medication), Crestor (Medication), Tagrisso (Medication), Bydureon (Medication)
Abstract

About Us AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing [...]

Published
2017

50. Teva settles generic Byetta patent litigation with AstraZeneca

Subjects
AstraZeneca Pharmaceuticals L.P. -- Licensing agreements, Teva Pharmaceuticals USA Inc. -- Licensing agreements, Hypoglycemic agents, Generic drugs -- Licensing agreements, Litigation, Pharmaceutical industry -- Licensing agreements, Lawsuit/litigation, Company licensing agreement, Pharmaceuticals and cosmetics industries, Byetta (Medication)
Abstract

Teva Pharmaceuticals USA, Inc., a leading global pharmaceutical company, announced that the company has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results